ArticleBMC cancer2017

Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway.

Xue Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.